These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36738675)

  • 1. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway.
    Zheng J; Lu Y; Xiao J; Duan Y; Zong S; Chen X; Hu T; Li L; Zhang Y
    Int Immunopharmacol; 2023 Mar; 116():109753. PubMed ID: 36738675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
    Jounaidi Y; Cotten JF; Miller KW; Forman SA
    Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat.
    Afolabi LO; Bi J; Li X; Adeshakin AO; Adeshakin FO; Wu H; Yan D; Chen L; Wan X
    Front Immunol; 2021; 12():701671. PubMed ID: 34531855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
    Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
    Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
    BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
    Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma.
    Liu YF; Chiang Y; Hsu FM; Tsai CL; Cheng JC
    Front Oncol; 2022; 12():1009089. PubMed ID: 36185276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells.
    Xia C; He Z; Cai Y; Liang S
    Eur J Pharmacol; 2020 May; 875():173057. PubMed ID: 32135122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2
    Medon M; Vidacs E; Vervoort SJ; Li J; Jenkins MR; Ramsbottom KM; Trapani JA; Smyth MJ; Darcy PK; Atadja PW; Henderson MA; Johnstone RW; Haynes NM
    Cancer Res; 2017 May; 77(10):2594-2606. PubMed ID: 28249907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.
    Lu X; Liu M; Yang J; Que Y; Zhang X
    Clin Exp Immunol; 2022 Aug; 209(2):127-139. PubMed ID: 35867577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.
    Son CH; Keum JH; Yang K; Nam J; Kim MJ; Kim SH; Kang CD; Oh SO; Kim CD; Park YS; Bae J
    Radiat Oncol; 2014 Feb; 9():49. PubMed ID: 24512718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.